Urvi M Parikh, Lauren D Kudrick , Everline Bosek , Bhavna H Chohan , Irene Mukui , Sarah Masyuko , Nonhlanhla Ndlovu , Imelda Mahaka , Owen Mugurungi , Gertrude Ncube , Anita Hettema , Sindy N Matse , Saiqa Mullick , Carole L Wallis ,
(Journal of the international AIDS Society, 2025-08)
Introduction: The ongoing rollout of oral tenofovir-based pre-exposure prophylaxis (PrEP) has the potential to reduce HIV-1 incidence, but HIV drug resistance (HIVDR) in individuals who acquire HIV-1 on PrEP could threaten ...